cancer radiotherapy News
-
Betaglue technologies strengthen its expertise in strategic areas with four new managers
Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Caia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas Clinical developments continue on the advanced cancer radiotherapy platform, BAT-90, as the first breast cancer patient was treated Milan, October 19, 2022 - BetaGlue Technologies, a highly innovative company working in the Life Sciences sector, ...
-
Radiotherapy That Could Halve Prostate Cancer Treatment Time Recommended For Use in Wales
Health Technology Wales (HTW) has published guidance recommending the routine adoption of Extreme Hypofractionated Radiotherapy (EHFRT) for the treatment of localised prostate. In the UK, prostate cancer is the most common cancer in men and in Wales, more than 2,500 men each year are diagnosed with prostate cancer. Radiotherapy is included as part of primary treatment in approximately 30% of ...
By MediWales
-
BetaGlue strengthen its expertise in strategic areas with four new managers
Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Gaia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas BetaGlue Technologies has appointed four new managers, strengthening the team across strategic fields for its business development: Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Gaia Bisaccioni joined the company in September in the ...
-
Galera Announces Plan to Submit Avasopasem NDA by Year End
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced its intent to file a New Drug Application (NDA) for avasopasem manganese (avasopasem) for the treatment of radiotherapy-induced severe oral mucositis ...
-
Showcase
RTsafe and Biomedic Medical Group sign exclusive agreement for distribution
RTsafe, a medical technology company focused on improving the safety and accuracy of radiotherapy for cancer and other medical conditions, today announced that Biomedic Medical Group will be the exclusive distributor of RTsafe’s products in China. We are delighted to announce this new collaboration and looking forward to provide our products to the Chinese radiotherapy professionals. ...
By RTsafe
-
BetaGlue has enrolled the first patient treated with BAT-90 in its First-in-Human trials, taking radiotherapy inside solid tumours
The first clinicalfindingshave shown that BAT-90makes it possible to treat onlythe area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatmentefficacy and patient safety BetaGlue Technologieshasenrolledthe first patientin a clinical trialwithBAT-90, the company’s cancer radiotherapy platform. The first clinical findings have shown thatBAT-90 ...
-
Shonan Kamakura Advanced Medical Center Begins Treatment with Hitachi`s First Dedicated Compact Proton Therapy System
Hitachi, Ltd. (TSE: 6501, ”Hitachi”) today announced that “Shonan Kamakura Advanced Medical Center” at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi's compact proton therapy system (hereafter, “the system”) has been installed, has commenced treatment with the system on 31 January 2022. This is the first order for Hitachi’s ...
-
Betaglue takes radiotherapy inside solid tumours: first patient treated
The first clinical results have shown that BAT-90 innovative radiotherapy platform makes it possible to treat only the area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatment efficacy and patient safety CEO/CMO, Dr. Antonino Amato, said: "The confirmation in this first patient of the previous findings from the pre-clinical studies with BAT-90 opens ...
-
Galera to Present at Jefferies Healthcare Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at ...
-
Galera to Present at H.C. Wainwright BioConnect Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, taking place January ...
-
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis ...
-
C4 Imaging Announces FDA 510(k) Clearance of its Non-metallic, Multimodality C4 Fiducial Marker
C4 Imaging LLC announces U.S. Food and Drug Administration 510(k) clearance of its third major product, the Multimodality C4 Fiducial Marker. This novel positive-signal MRI marker will be implanted into patients in situations where the location of specific anatomy, normal or diseased, needs to be marked for a future medical procedure. The device can be visualized using MRI, CT or x-ray, and ...
-
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that clinical data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis will be presented in an oral presentation at the upcoming ...
-
Atomic energy agency marks World Cancer Day
World Cancer Day is marked each year on 4 February to raise awareness of the far-reaching impact of cancer and the need to mobilize efforts to combat the disease. Today, as global cancer levels continue to rise, the message is becoming increasingly urgent. The World Health Organization (WHO) says that unless action is taken now, more than 84 million people will die of cancer over the next ten ...
-
CTT to Present Data on Prostate Cancer Therapy Candidates at Upcoming Conferences
The most recent performance data on Cancer Targeted Technology’s (CTT) leading drugs, CTT1057 and CTT1403, in prostate cancer clinical and preclinical studies will be presented at several scientific and business meetings in June and one that took place in April, the company announced in a press release. The meetings featuring CTT presentations include the American Society of Clinical ...
-
Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem
Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045) Topline results from single-arm Phase 2a trial of avasopasem in Europe in line with the ROMAN trial results Company plans to discuss avasopasem data with the FDA in 2022 Company to host conference call and live ...
-
Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis
No Grade 4 or 5 esophagitis in patients treated with avasopasem Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced topline results from the six-week, Phase 2a, open-label, single-arm AESOP trial of ...
-
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government’s Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, has awarded Chrysalis a contract (HHSO100201900016C) to support the continued development of TP508, rusalatide acetate, as a ...
-
TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the successful installation of its neutron beam system at Xiamen Humanity Hospital, the most advanced accelerator-based BNCT facility in Greater China, newly built in partnership with Neuboron Medical Group. TLS’ Neutron Beam System ...
-
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting
BURLINGTON, Mass. and OXFORD, UK, October 19, 2021 - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced presentations on Axumin® (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting, to be held in Chicago, III., ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you